From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Clinical data
CAS Number
PubChem CID
ECHA InfoCard100.235.008 Edit this at Wikidata
Chemical and physical data
Molar mass446.555 g·mol−1
3D model (JSmol)

Erdafitinib[1] is a small molecule inhibitor of FGFR approved for treatment of cancer and marketed under the name Balversa. FGFRs are a subset of tyrosine kinases which are unregulated in some tumors and influence tumor cell differentiation, proliferation, angiogenesis, and cell survival.[2] Astex Pharmaceuticals discovered the drug and licensed it to Janssen Pharmaceuticals for further development.

Researchers have investigated erdafitinib for safety and efficacy in treatment of cholangiocarcinoma, gastric cancer, non-small cell lung cancer, and esophageal cancer.[3]

In March 2018, erdafitinib was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for treatment of urothelial cancer.[2]

In April 2019, erdafitinib was granted approval by the FDA for treatment of metastatic or locally advanced bladder cancer with an FGFR3 or FGFR2 alteration that has progressed beyond traditional platinum-based therapies, subject to a confirmatory trial.[4]


  1. ^
  2. ^ a b "Janssen Announces U.S. FDA Breakthrough Therapy Designation for Erdafitinib in the Treatment of Metastatic Urothelial Cancer - Johnson & Johnson".
  3. ^ "Erdafitinib - Janssen Pharmaceutica - AdisInsight".
  4. ^ "FDA approves first targeted therapy for metastatic bladder cancer". Retrieved 2019-05-13.